Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting

Cited by (335)

Items 101–200 of 335

1. TALEN-edited allogeneic inducible dual CAR T cells enable effective targeting of solid tumors while mitigating off-tumor toxicity
   Sonal Dharani, Hana Cho, Jorge Postigo, Alexandre Juillerat, Julien Valton, Philippe N. Duchateau, Laurent Poirot, Shipra Das · 2024 · Molecular Therapy
2. Application of novel CAR technologies to improve treatment of autoimmune disease
   Abigail Cheever, Chloe Kang, Kim Leslie O'Neill, K. Scott Weber · 2024 · Frontiers in Immunology
3. Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors
   Marion Alcantara, Pauline du Rusquec, Emanuela Romano · 2020 · OncoImmunology
4. Expamers: a new technology to control T cell activation
   Mateusz P. Poltorak, Patricia Graef, Claudia Tschulik, Michaela M. Wagner, Vlad Cletiu, Stefan Dreher, Bojana Borjan, Simon P. Fräßle, Manuel J. P. Effenberger, Martin Turk et al. · 2020 · Scientific Reports
5. Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism
   Torahito A. Gao, Yvonne Y. Chen · 2022 · Annual Review of Chemical and Biomolecular Engineering
6. ROR1-targeting switchable CAR-T cells for cancer therapy
   Haiyong Peng, Thomas Nerreter, Katrin Mestermann, Jakob Wachter, Jing Chang, Michael Hudecek, Christoph M. Rader · 2022 · Oncogene
7. Microbial metabolites are involved in tumorigenesis and development by regulating immune responses
   Jiahui Liu, Ruxian Tian, Caiyu Sun, Ying Guo, Lei Dong, Yumei Li, Xicheng Song · 2023 · Frontiers in Immunology
8. Therapeutic advances in the targeting of ROR1 in hematological cancers
   Adrian-Bogdan Tigu, Raluca Andrada Munteanu, Cristian Silviu Moldovan, Rareş Drulă, Dávid Kegyes, Radu Andrei Tomai, Vlad Moisoiu, Gabriel Ghiaur, Ciprian Tomuleasa, Hermann Einsele et al. · 2024 · Cell Death Discovery
9. Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens
   Michael S. Hwang, Michelle S. Miller, Puchong Thirawatananond, Jacqueline Douglass, Katharine M. Wright, Emily Han-Chung Hsiue, Brian J. Mog, Tihitina Y. Aytenfisu, Michael B. Murphy, P. Aitana Azurmendi et al. · 2021 · Nature Communications
10. Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity
    Taisuke Kondo, François X. P. Bourassa, Sooraj R. Achar, Justyn DuSold, Pablo F. Céspedes, Makoto Ando, Alka Dwivedi, Josquin Moraly, Christopher Daniel Chien, Saliha Majdoul et al. · 2025 · Cell
11. Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer
    Carlos Mauricio Moreno, Christopher Haynie, Abigail Cheever, K. Scott Weber · 2022 · Biomedicines
12. Rationally designed approaches to augment CAR-T therapy for solid tumor treatment
    Chaojie Zhu, Qing Wu, Tao Sheng, Jiaqi Shi, Xinyuan Shen, Jicheng Yu, Yang Du, Jie Sun, Tingxizi Liang, Kaixin He et al. · 2023 · Bioactive Materials
13. Current status and future challenges of CAR-T cell therapy for osteosarcoma
    Shizhe Li, He Zhang, Guanning Shang · 2023 · Frontiers in Immunology
14. SyNPL: Synthetic Notch pluripotent cell lines to monitor and manipulate cell interactions in vitro and in vivo
    Mattias Malaguti, Rosa Portero Migueles, Jennifer Annoh, Daina Sadurska, Guillaume Blin, Sally Lowell · 2022 · Development
15. CAR‐T‐cell products in solid tumors: Progress, challenges, and strategies
    Kewen Qian, Guangyao Li, Shuyi Zhang, Wenyan Fu, Tian Li, Jian Zhao, Changhai Lei, Yuqing Wang, Shi Hu · 2024 · Interdisciplinary medicine
16. Engineering CAR T cells for enhanced efficacy and safety
    Yiqian Wu, Ziliang Huang, Reed E. S. Harrison, Longwei Liu, Linshan Zhu, Yinglin Situ, Yingxiao Wang · 2022 · APL Bioengineering
17. Synthetic Biology in the Engineering of CAR-T and CAR-NK Cell Therapies: Facts and Hopes
    Justin D. Clubb, Torahito A. Gao, Yvonne Y. Chen · 2022 · Clinical Cancer Research
18. CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them
    Jolien Vanhooren, Rani Dobbelaere, Charlotte Derpoorter, Larissa Deneweth, Laurens Van Camp, Anne Uyttebroeck, Barbara De Moerloose, Tim Lammens · 2023 · HemaSphere
19. YAP/BRD4‐controlled ROR1 promotes tumor‐initiating cells and hyperproliferation in pancreatic cancer
    Masaya Yamazaki, Shinjiro Hino, Shingo Usuki, Yoshihiro Miyazaki, Tatsuya Oda, Mitsuyoshi Nakao, Takaaki Ito, Kazuya Yamagata · 2023 · The EMBO Journal
20. Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification
    Marco Cortese, Erica Torchiaro, Alice D'Andrea, Consalvo Petti, Federica Invrea, Letizia Franco, Chiara Donini, Valeria Leuci, Simonetta Maria Leto, Valentina Vurchio et al. · 2024 · Molecular Therapy
21. CAR T Cell Therapy Progress and Challenges for Solid Tumors
    Lawrence A. Stern, Vanessa D. Jönsson, Saul J. Priceman · 2020 · Cancer treatment and research
22. Overcoming Stromal Barriers to Immuno-Oncological Responses via Fibroblast Activation Protein-Targeted Therapy
    William Nathaniel Brennen, Daniel L.J. Thorek, Wen Jiang, Timothy E. G. Krueger, Lizamma Antony, Samuel Ray Denmeade, John T. Isaacs · 2020 · Immunotherapy
23. CAR-armored-cell therapy in solid tumor treatment
    Yan Liu, Lin Xiao, Mingxuan Yang, Xuemei Chen, Hongyue Liu, Quanxing Wang, Meng Guo, Jianhua Luo · 2024 · Journal of Translational Medicine
24. Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity
    Kristen C. Vogt, Pedro C. Silberman, Qianqian Lin, James E. Han, Amy D. Laflin, Hendryck A. Gellineau, Daniel A. Heller, David A. Scheinberg · 2025 · Science Advances
25. Activation-inducible CAR expression enables precise control over engineered CAR T cell function
    Simon P. Fraessle, Claudia Tschulik, Manuel Effenberger, Vlad Cletiu, Maria Gerget, Kilian Schober, D. Busch, L. Germeroth, C. Stemberger, M. Póltorak · 2022 · bioRxiv
26. Improved safety of chimeric antigen receptor T cells indirectly targeting antigens via switchable adapters
    Hyung Bae Park, Ki Hyun Kim, Ju Hwan Kim, Sang Il Kim, Yu Mi Oh, Miseung Kang, Seoho Lee, Siwon Hwang, Hyeonmin Lee, TaeJin Lee et al. · 2024 · Nature Communications
27. Building sophisticated sensors of extracellular cues that enable mammalian cells to work as “doctors” in the body
    Ryosuke Kojima, Dominque Aubel, Martin Fussenegger · 2020 · Cellular and Molecular Life Sciences
28. Better by design: What to expect from novel CAR-engineered cell therapies?
    Vera Luginbuehl, Eytan Abraham, Karin Kovar, Richard Flaaten, Antonia M. S. Müller · 2022 · Biotechnology Advances
29. Notch Pathway: A Journey from Notching Phenotypes to Cancer Immunotherapy
    Giulia Monticone, Lucio Miele · 2020 · Advances in experimental medicine and biology
30. The Tmod cellular logic gate as a solution for tumor-selective immunotherapy
    Breanna DiAndreth, Agnes E. Hamburger, Xu Han, Alexander Kamb · 2022 · Clinical Immunology
31. The effects of electron scattering and wind clumping for early emission line stars
    Desmond John Hillier · 1991
32. Synthetic transcription factor engineering for cell and gene therapy
    Bhoomi Bhatt, Pablo García-Díaz, G. Wink · 2023 · Trends in biotechnology
33. Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair
    Beau R. Webber, Matthew J. Johnson, Joseph G. Skeate, Nicholas J. Slipek, Walker S. Lahr, Anthony P. DeFeo, Lauren J. Mills, Xiaohong Qiu, Blaine Rathmann, Miechaleen D. Diers et al. · 2023 · Nature Biomedical Engineering
34. CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives
    Rebecca Epperly, Stephen M Gottschalk, Christopher C. DeRenzo · 2024 · EJC Paediatric Oncology
35. Current state of CAR-T therapy for T-cell malignancies
    Liangkui Luo, Xuan Zhou, Lijuan Zhou, Zhao Liang, Jilong Yang, Sanfang Tu, Yuhua Li · 2022 · Therapeutic Advances in Hematology
36. Recent progress of gene circuit designs in immune cell therapies
    Seung‐Hee Lee, Ahmad S. Khalil, Wilson W. Wong · 2022 · Cell Systems
37. Inhibitory CARs fail to protect from immediate T cell cytotoxicity
    Maximilian A. Funk, Gerwin Heller, Petra Waidhofer‐Söllner, Judith Maria Leitner, Peter Steinberger · 2024 · Molecular Therapy
38. Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment
    Xianjun Li, Tianjun Chen, Xuehan Li, Hanyu Zhang, Yingjing Li, Shuyuan Zhang, Shengnan Luo, Tongsen Zheng · 2024 · Experimental Hematology and Oncology
39. Genetic circuits in synthetic biology: broadening the toolbox of regulatory devices
    Marik M. Müller, Katja M. Arndt, Stefan A. Hoffmann · 2025 · Frontiers in Synthetic Biology
40. Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors
    Hinrich Abken · 2021 · Human Gene Therapy
41. Immunobiology of chimeric antigen receptor T cells and novel designs
    Zachary H. Walsh, Yinmeng Yang, Mark Eric Kohler · 2019 · Immunological Reviews
42. Anti-ROR1 CAR-T cells: Architecture and performance
    Daniel Andrés Osorio-Rodríguez, Bernardo Camacho, Cesar A. Ramirez-Segura · 2023 · Frontiers in Medicine
43. A Novel Treatment for Ewing’s Sarcoma: Chimeric Antigen Receptor-T Cell Therapy
    Zili Lin, Ziyi Wu, Wei Luo · 2021 · Frontiers in Immunology
44. Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy
    Hyunmin Chung, Haiyoung Jung, Ji‐Yoon Noh · 2021 · International Journal of Molecular Sciences
45. Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia
    Marius Maucher, Micha Srour, Sophia Danhof, Hermann Einsele, Michael Hudecek, Ibrahim Yakoub‐Agha · 2021 · Cancers
46. Sonogenetic control of multiplexed genome regulation and base editing
    Pei Liu, Josquin L. Foiret, Yinglin Situ, Nisi Zhang, Aris J. Kare, Bo Wu, Marina Nura Raie, Katherine W. Ferrara, Lei S. Qi · 2023 · Nature Communications
47. Anti–PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers
    Karsten Eichholz, Yoshinori Fukazawa, Christopher W. Peterson, Françoise Haeseleer, Manuel Medina, Shelby T. Hoffmeister, Derick M. Duell, Benjamin D. Varco-Merth, Sandra Dross, Haesun Park et al. · 2024 · Journal of Clinical Investigation
48. CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells
    Samy Jambon, Jianping Sun, Shawn Barman, Sakunthala Muthugounder, Xue Rachel Bito, Armita Shadfar, Alexandra E. Kovach, Brent Lee Wood, Varsha Thoppey Manoharan, A. Sorana Morrissy et al. · 2024 · Blood Cancer Discovery
49. Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer
    Hany E. S. Marei, Khaled Bedair, Anwarul Hasan, Layla Al-Mansoori, Sara Caratelli, Giuseppe Sconocchia, Alice Gaiba, Carlo Cenciarelli · 2025 · Cancer Cell International
50. Therapeutic roles of CAR T cells in infectious diseases: Clinical lessons learnt from cancer
    Mahsa Mohammadi, Maryam Akhoundi, Sara Malih, Ali Mohammadi, Mohsen Sheykhhasan · 2022 · Reviews in Medical Virology
51. Developing ROR1 Targeting CAR-T Cells against Solid Tumors in Preclinical Studies
    Boon kiat Lee, Yuhua Wan, Lynn Chin, Linyan Deng, Mo Deng, Tze ming Leung, Jianhua Ma, Hua Zhang · 2022 · Cancers
52. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer
    Yu Cao, Sergey K. Efetov, Mingze He, Yu Fu, Narasimha Murthy Beeraka, Jin Zhang, Xinliang Zhang, Namitha Bannimath, Kuo Chen · 2023 · Archivum Immunologiae et Therapiae Experimentalis
53. Design and development of engineered receptors for cell and tissue engineering
    Shwan B. Javdan, Tara L. Deans · 2021 · Current Opinion in Systems Biology
54. Synthetic receptors for logic gated T cell recognition and function
    Sylvain Simon, Grace Bugos, Alexander I. Salter, Stanley R. Riddell · 2021 · Current Opinion in Immunology
55. De Novo Discovery of Cysteine Frameworks for Developing Multicyclic Peptide Libraries for Ligand Discovery
    Jinjing Li, Hongtan Liu, Shuling Xiao, Shihui Fan, Xueting Cheng, Chuanliu Wu · 2023 · Journal of the American Chemical Society
56. Engineering a Programmed Death-Ligand 1-Targeting Monobody Via Directed Evolution for SynNotch-Gated Cell Therapy
    Linshan Zhu, Chi‐Wei Man, Reed E. S. Harrison, Zhuohang Wu, Praopim Limsakul, Peng Qin, Matthew Hashimoto, Anthony P. Mamaril, Hongquan Xu, Longwei Liu et al. · 2024 · ACS Nano
57. The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies
    Andriy Zhylko, Magdalena Winiarska, Agnieszka Graczyk‐Jarzynka · 2020 · Cancers
58. Avidity‐Based Selection of Tissue‐Specific CAR‐T Cells from a Combinatorial Cellular Library of CARs
    Peixiang Ma, Ping Ren, Chuyue Zhang, Jiaxing Tang, Zheng Yu, Xuekai Zhu, Kun Fan, Guanglei Li, Wei Zhu, Wei Sang et al. · 2021 · Advanced Science
59. CAR Based Immunotherapy of Solid Tumours—A Clinically Based Review of Target Antigens
    John F. Maher, David Marc Davies · 2023 · Biology
60. Evolving strategies for addressing CAR T-cell toxicities
    Alexander W. Rankin, Brynn B. Duncan, Cecily Allen, Sara K. Silbert, Nirali N. Shah · 2024 · Cancer and Metastasis Reviews
61. JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment
    Javad Khanali, Mohammadreza Azangou‐Khyavy, Melika Boroomand-Saboor, Mobina Ghasemi, Hassan Niknejad · 2021 · Frontiers in Immunology
62. Industrializing engineered autologous T cells as medicines for solid tumours
    Cedrik Michael Britten, Aiman M. Shalabi, Axel Hoos · 2021 · Nature Reviews Drug Discovery
63. Chimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma
    Zili Lin, Ziyi Wu, Wei Luo · 2021 · Cancers
64. Multiplexed engineering and precision gene editing in cellular immunotherapy
    Alexander Biederstädt, Gohar Shahwar Manzar, May Daher · 2022 · Frontiers in Immunology
65. Natural killer cell engineering – a new hope for cancer immunotherapy
    Cheng‐Yu Lin, Ilan Gobius, Fernando Souza-Fonseca-Guimarães · 2020 · Seminars in Hematology
66. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting
    Georgina S.F. Anderson, Michael A. Chapman · 2024 · Molecular Therapy
67. Programmable Smart CAR-T design: A new paradigm in precision immunotherapy driven by logic gates, conditional activation, allogeneic strategies, and artificial intelligence
    Peizhen Wen, Qi Ai, Xiang Fan, Zhangyuan Gu, 陈波, Hui Qian · 2026 · Cancer Letters
68. Emerging mammalian gene switches for controlling implantable cell therapies
    Oliver Madderson, Ana P. Teixeira, Martin Fussenegger · 2021 · Current Opinion in Chemical Biology
69. Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy
    Mohadeseh Mohammad Taheri, Fatemeh Javan, Mohadeseh Poudineh, Seyed Shamseddin Athari · 2024 · Journal of Translational Medicine
70. Novel humanized monoclonal antibodies against ROR1 for cancer therapy
    Rong Wei, Xun Liao, Jiao Li, Xiaoyu Mu, Yue Ming, Yong Peng · 2024 · Molecular Cancer
71. New targets and technologies for CAR-T cells
    Fabian Freitag, Marius Maucher, Zeno Riester, Michael Hudecek · 2020 · Current Opinion in Oncology
72. SALSA, a genetically encoded biosensor for spatiotemporal quantification of Notch signal transduction in vivo
    Justin M. Shaffer, Iva Greenwald · 2022 · Developmental Cell
73. IL-2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL-15
    Rachel A. Burga, Bülent Arman Aksoy, Zheng Ao, Jeremy H. Tchaicha, Dhruv K. Sethi, Alonso Villasmil Ocando, Gauri S. Kulkarni, Scott Lajoie, Kyle D. Pedro, Jack Ryan Tremblay et al. · 2025 · Molecular Therapy
74. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors
    Tao Yu, Shao-Kun Yu, Yan Xiang, Kaihua Lu, Ming Sun · 2022 · Frontiers in Immunology
75. Dual-target CAR-T cell therapy: A new strategy to improve the therapeutic effect of hematological malignancies
    Shenyu Wang, Xin Li, Hongmei Ning, Yamei Wu · 2025 · Critical Reviews in Oncology/Hematology
76. Fully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology
    Konstantinos Lontos, Yiyang Wang, Mason Colbert, Alok Kumar, Supriya K Joshi, Mary Philbin, Yupeng Wang, Andrew T. Frisch, Jason J. Lohmueller, Dayana B. Rivadeneira et al. · 2022 · OncoImmunology
77. Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors
    Jeremiah A. Wala, Glenn J. Hanna · 2023 · Hematology/Oncology Clinics of North America
78. Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers.
    Grace C. Russell, Yassin Hamzaoui, Daniel Rho, G. Sutrave, Joseph S. Choi, D. Missan, G. A. Reckard, Michael P. Gustafson, Gloria B. Kim · 2024 · Cytotherapy
79. Enhancing cell‐based therapies with synthetic gene circuits responsive to molecular stimuli
    Silvia Galvan, Ana P. Teixeira, Martin Fussenegger · 2024 · Biotechnology and Bioengineering
80. Progress in the development of cytokine armoured CAR T cells
    Krishneel Prasad, Ryan Stanley Cross, Misty Rayna Jenkins · 2026 · Nature reviews. Immunology
81. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook
    Hao Zhang, Shuangli Zhu, Wanjun Deng, Rui Li, Haiting Zhou, Huihua Xiong · 2022 · Frontiers in Immunology
82. Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential
    Diego F. Chamorro, Lauren K. Somes, Valentina Hoyos · 2023 · Cancers
83. New player in CAR-T manufacture field: comparison of umbilical cord to peripheral blood strategies
    Karolina Rassek, Jan Misiak, Tomasz Ołdak, Natalia Rozwadowska, Grzegorz Władysław Basak, Tomasz Jan Kolanowski · 2025 · Frontiers in Immunology
84. B7-H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors
    Lena Jansen, Judith Wienke, Ronja Molkenbur, Claudia Rössig, Ramona Meissner · 2025 · Cancer and Metastasis Reviews
85. CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation
    Reza Elahi, Yassine Alami Idrissi, Anwaar Saeed · 2025 · Cancer Treatment Reviews
86. Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting
    Ángeles Ocaña-Cara, Tuna Mutis, Jort J. van der Schans · 2025 · Experimental Hematology and Oncology
87. Recent Advances in Single-Cell Profiling and Multispecific Therapeutics: Paving the Way for a New Era of Precision Medicine Targeting Cardiac Fibroblasts
    Sally Yu Shi, Xin Luo, Tracy Yamawaki, Chi-Ming Li, Brandon L. Ason, Milena Bastos Furtado · 2021 · Current Cardiology Reports
88. Significant Advancements and Evolutions in Chimeric Antigen Receptor Design
    Anna Gaimari, Anna De Lucia, F. Nicolini, Luciana Mazzotti, R. Maltoni, Giovanna Rughi, Matteo Zurlo, Matteo Marchesini, M. Juan, D. Parras et al. · 2024 · International Journal of Molecular Sciences
89. Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects
    Azam Bozorgi, Maryam Bozorgi, Mozafar Khazaei · 2022 · Cellular Oncology
90. Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction
    Artemis Gavriil, Marta Barisa, Emma Halliwell, John Anderson · 2020 · Cancers
91. Overcoming key challenges in cancer immunotherapy with engineered T cells
    Silvia Arcangeli, Katrin Mestermann, Justus Weber, Chiara Bonini, Monica Casucci, Michael Hudecek · 2020 · Current Opinion in Oncology
92. Engineering a Second‐Order DNA Logic‐Gated Nanorobot to Sense and Release on Live Cell Membranes for Multiplexed Diagnosis and Synergistic Therapy
    Dan Wang, Shen‐Huan Li, Zilong Zhao, Xiaobing Zhang, Weihong Tan · 2021 · Angewandte Chemie
93. Emerging strategies and novel therapeutic targets in acute myeloid leukemia: current advances and future directions
    Linyu Cao, Zhe Wang, Yimin Cui, Yuan Li, Qian Xiang · 2025 · Biomarker Research
94. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T
    Tim Andrew Erickson, Yi-Ping Shih, Joseph N Fass, Myungkyu Jang, Eric Tran · 2022 · Thyroid
95. Recent advances in synthetic Notch receptors for biomedical application
    Luyao Song, Qinmeng Zhang, Hairu Sui, Chenlu Gao, Zhiwei Jiang · 2025 · American Journal of Physiology-Cell Physiology
96. Systematic review of nutrition support interventions in adult haematology and oncology patients receiving CAR T cell therapy
    Brittany Cucchiaro, Christine Elizabeth Weekes · 2021 · Clinical Nutrition ESPEN
97. Intelligent cell-based therapies for cancer and autoimmune disorders
    Rui Chen, Jing Ji, Stefan K. Siwko, Yun Huang, Yubin Zhou · 2020 · Current Opinion in Biotechnology
98. Novel insights into cancer stem cells targeting: CAR-T therapy and epigenetic drugs as new pillars in cancer treatment
    Veronica Veschi, Alice Turdo, Giorgio Stassi · 2023 · Frontiers in Molecular Medicine
99. Arming Vδ2 T Cells with Chimeric Antigen Receptors to Combat Cancer
    Pauline Thomas, Pierre Paris, Claire Pecqueur · 2024 · Clinical Cancer Research
100. Short‐Chain Fatty Acids Modulate Anti‐ROR1 CAR T‐Cell Function and Exhaustion in an Intestinal Adenocarcinoma‐on‐Chip Model
     Valentin D. Wegner, Adrian Feile, Miriam Alb, Michael Hudecek, Philip G. Hewitt, Alexander Sandy Mosig · 2025 · Advanced Healthcare Materials